NCT04679740 Resorbable Magnesium Scaffolds Registry
| NCT ID | NCT04679740 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Biotronik AG |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,106 participants |
| Start Date | 2020-11-18 |
| Primary Completion | 2030-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,106 participants in total. It began in 2020-11-18 with a primary completion date of 2030-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).
Eligibility Criteria
Inclusion Criteria: * According to the IFU Exclusion Criteria: * According to the IFU
Contact & Investigator
Stefano Galli, MD
PRINCIPAL INVESTIGATOR
Centro Cardiologico Monzino
Frequently Asked Questions
Who can join the NCT04679740 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04679740 currently recruiting?
Yes, NCT04679740 is actively recruiting participants. Contact the research team at marina.gattiglio@teleflex.com for enrollment information.
Where is the NCT04679740 trial being conducted?
This trial is being conducted at Cairns, Australia, Bad Segeberg, Germany, Buchholz, Germany, Dortmund, Germany and 9 additional locations.
Who is sponsoring the NCT04679740 clinical trial?
NCT04679740 is sponsored by Biotronik AG. The principal investigator is Stefano Galli, MD at Centro Cardiologico Monzino. The trial plans to enroll 1,106 participants.